Treatment of Idiopathic Pulmonary Fibrosis with Etanercept

Raghu, Ganesh; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Bois, Roland M. du; Lasky, Joseph A.; Thomeer, Michiel; Utz, James P.; Khandker, Rezaul Karim; McDermott, Lawrence; Fatenejad, Saeed

doi:10.1164/rccm.200709-1446oc

Cited by 333 publications

(210 citation statements)

References 41 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…A randomised, double-blind, placebo-controlled phase II trial explored the effect of etanercept on the change in FVC from baseline to week 48. Although the drug was well tolerated it failed to satisfy the primary end-point; however, some nonsignificant trends in DLCO and 6MWT were observed [67].…”

Section: Interferon-cmentioning

confidence: 94%

Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

Αντωνίου

Margaritopoulos

Siafakas

2013

European Respiratory Review

View full text Add to dashboard Cite

During the past decade important progress has been made regarding the pathogenesis of idiopathic pulmonary fibrosis (IPF), which is the most devastating form of idiopathic interstitial pneumonia with a median survival of 3 years. The knowledge gained has been used to design multicentre, randomised, placebo-controlled trials in order to investigate agents with different mechanisms of action. Encouraging results have led to licensing of the first IPF-specific drug, pirfenidone. However, the road to successful treatment is still long. The main aim for the future should be the careful design of clinical trials, by choosing the most clinically meaningful end-point and keeping in mind that combination of various agents may be more effective. This approach has been used in the treatment of lung cancer with which IPF presents many similarities. @ERSpublications Progress toward the treatment of IPF and aims for future clinical trials

show abstract

Section: Interferon-cmentioning

confidence: 94%

Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

Αντωνίου

Margaritopoulos

Siafakas

2013

European Respiratory Review

View full text Add to dashboard Cite

show abstract

“…No differences in the predefined endpoints (Raghu et al, 2008) Everolimus mTOR inhibitorproliferation signal inhibitor…”

Section: Tnf Inhibitormentioning

confidence: 99%

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

Spagnolo¹,

Maher²,

Richeldi³

2015

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades our understanding of disease pathogenesis has substantially evolved and novel compounds have been developed consequent to the increasing knowledge of the mechanisms underlying disease pathobiology. The disease appears to be driven - following chronic injury - by abnormal/dysfunctional alveolar epithelial cells that promote fibroblast recruitment and proliferation, resulting in scarring of the lung and irreversible loss of function. With very few exceptions, clinical trials evaluating novel potential therapies have provided disappointing results. More recently, pirfenidone and nintedanib, two compounds with pleiotropic mechanisms of action, have proven effective in slowing functional decline and disease progression in IPF patients with mild to moderate functional impairment, highlighting the importance of timely diagnosis and administration of treatment in early stages of disease. However, due to the complexity and uncertainties intrinsic to IPF, it is essential that each therapeutic strategy be tailored to the individual patient, after evaluation of potential benefits and risks. This article provides an overview of the most recent clinical trials in IPF and discusses how their results are going to change the clinical and clinical research landscape in IPF. A number of agents with high potential are currently being tested and many more are ready for clinical trials. Their completion is critical for achieving the ultimate goal of curing patients with IPF

show abstract

“…In a 48-week, randomized, double blind, placebo-controlled, multicenter, Phase II trial, Raghu and coworkers evaluated safety and efficacy of subcutaneous (25 mg twice weekly) etanercept, a soluble TNF-alpha receptor antagonist that is used to treat rheumatoid arthritis, in subjects with IPF [17]. No significant differences in primary endpoints (changes in FVC % predicted, DLCO % predicted, and oxygenation at rest) were observed between the groups.…”

Section: Etanerceptmentioning

confidence: 99%

Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going

Luppi

Spagnolo

Cerri

et al. 2012

Curr Respir Care Rep

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the most common and most lethal diffuse fibrosing lung disease, with an increasing incidence and a mortality rate that exceeds that of many types of cancer. At present, there is no effective standard treatment recommended by guideline documents. As such, the unmet medical need is high. Recently, several high-quality clinical trials, evaluating safety and efficacy of different novel molecules, have been concluded. The results have mostly been disappointing, although some compounds have shown promising results. In particular, pirfenidone seems to be the most advanced molecule for IPF treatment, having been approved in Europe, Japan and India. Nintedanib, a triple kinase inhibitor, has almost completed enrolment of Phase III trials, based on promising Phase II results. Randomized controlled trials still represent a valid choice for IPF patients, and their completion is critically important to achieving the ultimate goal of curing IPF. Future approaches will probably include the evaluation of currently available agents alone and in combination, the identification of novel drugs with pleiotropic actions, and trials with validated, weighted composite endpoints.

show abstract

Treatment of Idiopathic Pulmonary Fibrosis with Etanercept

Cited by 333 publications

References 41 publications

Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going

Contact Info

Product

Resources

About